Lee Silverman voice treatment versus standard NHS speech and language therapy versus control in Parkinson's Disease (PD COMM pilot): study protocol for a randomised controlled trial

Catherine M. Sackley, Christina H. Smith, Caroline Rick, Marian C. Brady, Natalie Ives, Ramilla Patel, Helen Roberts, Francis Dowling, Susan Jowett, Keith Wheatley, Smitta Patel, Debbie Kelly, Gina Sands, Carl Clarke

Research output: Contribution to journalArticlepeer-review

17 Citations (Scopus)
12 Downloads (Pure)

Abstract

BACKGROUND: Parkinson's disease is a common movement disorder affecting approximately 127,000 people in the UK, with an estimated two thirds having speech-related problems. Currently there is no preferred approach to speech and language therapy within the NHS and there is little evidence for the effectiveness of standard NHS therapy or Lee Silverman voice treatment. This trial aims to investigate the feasibility and acceptability of randomizing people with Parkinson's disease-related speech or voice problems to Lee Silverman voice treatment or standard speech and language therapy compared to a no-intervention control.

METHODS/DESIGN: The PD COMM pilot is a three arm, assessor-blinded, randomized controlled trial. Randomization will be computer-generated with participants randomized at a ratio of 1:1:1. Participants randomized to intervention arms will be immediately referred to the appropriate speech and language therapist. The target population are patients with a confirmed diagnosis of idiopathic Parkinson's disease who have problems with their speech or voice. The Lee Silverman voice treatment intervention group will receive the standard regime of 16 sessions between 50 and 60 minutes in length over four weeks, with extra home practice. The standard speech and language therapy intervention group will receive a dose determined by patients' individual needs, but not exceeding eight weeks of treatment. The control group will receive standard care with no speech and language therapy input for at least six months post-randomization. Outcomes will be assessed at baseline (pre-randomization) and post- randomization at three, six, and 12 months. The outcome measures include patient-reported voice measures, quality of life, resource use, and assessor-rated speech recordings. The recruitment aim is at least 60 participants over 21 months from 11 sites, equating to at least 20 participants in each arm of the trial. This trial is ongoing and recruitment commenced in May 2012.

DISCUSSION: This study will provide information on the feasibility and acceptability of randomizing participants to different speech and language therapies or control/deferred treatment. The findings relating to recruitment, treatment compliance, outcome measures, and effect size will inform a future phase III randomized controlled trial.

TRIAL REGISTRATION: International Standard Randomised Controlled Trial Number Register: ISRCTN75223808 registered 22 March 2012.

Original languageEnglish
Article number213
Number of pages7
JournalTrials
Volume15
DOIs
Publication statusPublished - 7 Jun 2014

Keywords

  • Parkinson's disease
  • speech and language therapy
  • Lee Silverman voice treatment
  • randomised controlled trial
  • Speech and language therapy
  • Randomized controlled trial
  • Lee Silverman Voice Treatment
  • LSVT®
  • Voice Disorders/etiology
  • Humans
  • Pilot Projects
  • Parkinson Disease/complications
  • Voice Training
  • Speech Therapy/methods
  • Patient Compliance
  • Research Design
  • Voice

Fingerprint

Dive into the research topics of 'Lee Silverman voice treatment versus standard NHS speech and language therapy versus control in Parkinson's Disease (PD COMM pilot): study protocol for a randomised controlled trial'. Together they form a unique fingerprint.

Cite this